Replies to post #65073 on Innovation Pharmaceuticals Inc (IPIX)

[Tails]

Yes, that is accurate. "Of the outstanding."

But, when considering the fully diluted (with super voting) the numbers come close to what 58n posted.
Menon and Leo control the show. Period, dot, full stop.

Go CTIX!

[58nout]

oddone, this does not show the whole picture, From last year's 10K see the following:


Name and Address of Beneficial Owner
Amount and Nature of
Beneficial Owner (1) Percent of
Class (2)

Dr. Krishna Menon C/O Cellceutix(3)

100 Cumming Ctr., Suite 151-B

Beverley, MA 01915
49,048,286 41.4%


Leo Ehrlich (4) C/O Cellceutix

100 Cumming Ctr., Suite 151-B

Beverley, MA 01915
35,431,839 28.8%


All Directors and Executive

Officers as a Group (2 persons) (5)
84,480,125 59.9%



1. "Beneficial Owner" means having or sharing, directly or indirectly (i) voting power, which includes the power to vote or to direct the voting, or (ii) investment power, which includes the power to dispose or to direct the disposition, of shares of the common stock of an issuer. The definition of beneficial ownership includes shares, underlying options or warrants to purchase common stock, or other securities convertible into common stock, that currently are exercisable or convertible or that will become exercisable or convertible within 60 days. Unless otherwise indicated, the beneficial owner has sole voting and investment power.



2. For each shareholder, the calculation of percentage of beneficial ownership is based upon 99,073,984 shares of Common Stock outstanding as of June 30, 2013, and shares of Common Stock subject to options, warrants and/or conversion rights, including the conversion right of $0.50 for one share on Mr. Ehrlich’s convertible debt, held by the shareholder that are currently exercisable or exercisable within 60 days, which are deemed to be outstanding and to be beneficially owned by the shareholder holding such options, warrants, or conversion rights. The percentage ownership of any shareholder is determined by assuming that the shareholder has exercised all options, warrants and conversion rights to obtain additional securities and that no other shareholder has exercised such rights.



3. Krishna Menon, Chief Scientific Officer. Includes 18,000,000 vested options granted to him under the 2010 Equity Inventive Plan currently exercisable.



4. Leo Ehrlich, CEO, Chief Financial Officer and Director. (i) Includes 8,635,002 shares of Cellceutix common stock held by Mr. Ehrlich, (ii) includes 2,752,310 shares of Cellceutix’s common stock held by the wife of Leo Ehrlich, (iii) includes 4,044,527 shares of common stock into which the convertible loan in the amount of $2,022,527 would be convertible at $.50 per share deemed to be outstanding, (iv) includes 18,000,000 vested options granted to him under the 2010 Equity Incentive Plan currently exercisable and (v) includes 2,000,000 options issued to him on May 8, 2012.



5. Includes 84,480,125 shares of Common Stock directly and indirectly owned by the Executive Officers and Directors as a group, family members (see 4.), convertible loans (see 4.), and vested options (see 3. and 4.).